Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.62 |
| ▸ | KDR | P35968 | 5/20 | 0.62 |
| ▸ | EGFR | P00533 | 7/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | RET | P07949 | 3/20 | 0.44 |
| ▸ | KIF5B | P33176 | 1/20 | 0.44 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673970 | 0.91 | KDR (0.67) | SRCKDREGFRAURKAKCNH2 | |
| SCHEMBL6881082 | 0.91 | KDR (0.66) | SRCKDREGFRAURKAKCNH2 | |
| SCHEMBL3671772 | 0.91 | KDR (0.66) | SRCKDREGFRAURKAKCNH2 | |
| SCHEMBL6881088 | 0.91 | KDR (0.66) | SRCKDREGFRAURKAKCNH2 | |
| SCHEMBL3676968 | 0.90 | SRC (0.76) | SRCKDREGFRKCNH2EPHA2 | |
| SCHEMBL3673251 | 0.89 | KDR (0.58) | SRCKDREGFRKCNH2RET | |
| SCHEMBL3668458 | 0.86 | KDR (0.62) | SRCKDREGFRAURKAKCNH2 | |
| SCHEMBL3202365 | 0.82 | SRC (0.60) | SRCKDREGFRAURKARET | |
| SCHEMBL3669402 | 0.82 | SRC (0.60) | SRCKDREGFRAURKARET | |
| SCHEMBL6055729 | 0.81 | KDR (0.60) | SRCKDREGFRRETKIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063733-A1 | Such as 4-(7-indolylamino)-6-methoxy-7-(3-morpholinopropoxy)-quinazoline; for treating solid tumors | ASTRAZENECA AB (SE) | 2004-04-01 | — | — | US | claimed |
| EP-1332141-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-08-06 | — | — | EP | claimed |
| WO-2002034744-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-05-02 | — | — | WO | claimed |
| EP-1562612-B1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE FOR USE IN THE TREATMENT OR PROPHLAXIX OF PANCREATIC CANCER | ASTRAZENECA AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| US-20040063733-A1 | Such as 4-(7-indolylamino)-6-methoxy-7-(3-morpholinopropoxy)-quinazoline; for treating solid tumors | ASTRAZENECA AB (SE) | 2004-04-01 | — | — | US | disclosed |
| EP-1332141-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002034744-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063733-A1 | Such as 4-(7-indolylamino)-6-methoxy-7-(3-morpholinopropoxy)-quinazoline; for treating solid tumors | MIF, CCNI, MMP7 | SRC 1355/4885KDR 1855/4885EGFR 862/4885 |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | SRC, PTPN4, PTPN1 | SRC 1/4885KDR 825/4885EGFR 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.